Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Unknown 2Recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 77Thoracic 29Head & Neck 12Lymphoid 6Gynecologic 5Other solid neoplasm 3Genitourinary 3CNS 3Breast 3Tumor-Agnostic 2Endocrine 2Sarcoma 1Other neoplasm 1NET 1Myeloid 1Dermatologic 1

Conditions

Carcinoma, Neuroendocrine 2Pancreatic Neoplasms 1Neuroendocrine Tumors 1

Interventions

lutetium Lu 177 dotatate 6Everolimus 6lanreotide 5anlotinib 5Temozolomide 5Injections 4Dexmedetomidine 4Cisplatin 4surufatinib 3Thyrotropin Alfa 3Sodium Chloride 3Saline Solution 3Blood Specimen Collection 3177Lu-octreotide, DOTA(0)-Tyr(3)- 3(177)Lu-DOTA-EB-TATE 3sintilimab 2penpulimab 2cabozantinib 2Surgical Procedures, Operative 2Sorafenib 2Rosiglitazone 2Radiotherapy 2Radiofrequency Ablation 2Positron Emission Tomography Computed Tomography 2Paclitaxel 2Nivolumab 2N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 2Metformin 2Magnetic Resonance Spectroscopy 2Lymph Node Excision 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Unknown × sintilimab × Endocrine × Clear all
NCT05627427 2022-11-25

Multi-cohort Study of Surufatinib Plus Sintilimab in Metastatic NEN and Pancreatic Carcinoma Who Failed Standard Chemotherapy

Tianjin Medical University Cancer Institute and Hospital

Phase 2 Unknown
60 enrolled
EndocrineGastrointestinal

Pancreatic Neoplasms, Carcinoma, Neuroendocrine

NCT05113355 2021-11-24

Chidamide Plus Sintilimab for Chemotherapy-refractory Advanced High-grade Neuroendocrine Neoplasm

Peking Union Medical College Hospital

Phase 2 Unknown
23 enrolled
EndocrineNET

Carcinoma, Neuroendocrine, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡